{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:19:10Z","timestamp":1759421950345,"version":"3.37.3"},"reference-count":52,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T00:00:00Z","timestamp":1512604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T00:00:00Z","timestamp":1512604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Ministry of Health project","award":["CO-2013-02356463"],"award-info":[{"award-number":["CO-2013-02356463"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatologic Therapy"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1111\/dth.12565","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T10:18:46Z","timestamp":1512641926000},"page":"e12565","source":"Crossref","is-referenced-by-count":4,"title":["Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey"],"prefix":"10.1155","volume":"31","author":[{"given":"Maria C.","family":"Potenza","sequence":"first","affiliation":[{"name":"UOC di Dermatologia \u201cDaniele Innocenzi\u201d, Universit\u00e0 degli Studi \u201cSapienza\u201d Roma I facolt\u00e0 di Medicina e Chirurgia, Polo Pontino; Terracina LT Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Istituto di Dermatologia Policlinico Gemelli; Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Berardesca","sequence":"additional","affiliation":[{"name":"Ambulatorio Psoriasi IFO-San Gallicano; Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica, Dipartimento di Medicina dei Sistemi, Universita Tor Vergata; Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Richetta","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica, Dipartimento di Medicina dei Sistemi, Universita Tor Vergata; Rome Italy"},{"name":"Centro psoriasi, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche, Universit\u00e0 \u201cLa Sapienza\u201d Policlinico Umberto I; Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia \u201cDaniele Innocenzi\u201d, Universit\u00e0 degli Studi \u201cSapienza\u201d Roma I facolt\u00e0 di Medicina e Chirurgia, Polo Pontino; Terracina LT Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[{"name":"Istituto di Dermatologia Policlinico Gemelli; Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Teoli","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica, Dipartimento di Medicina dei Sistemi, Universita Tor Vergata; Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Zangrilli","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica, Dipartimento di Medicina dei Sistemi, Universita Tor Vergata; Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"D'epiro","sequence":"additional","affiliation":[{"name":"Centro psoriasi, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche, Universit\u00e0 \u201cLa Sapienza\u201d Policlinico Umberto I; Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Orsini","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica, Dipartimento di Neuroscienze Salute Mentale e Organi di Senso (NESMOS); Universit\u00e0 Sapienza- Azienda Ospedaliera Sant'Andrea; Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica, Dipartimento di Neuroscienze Salute Mentale e Organi di Senso (NESMOS); Universit\u00e0 Sapienza- Azienda Ospedaliera Sant'Andrea; Rome Italy"},{"name":"Humanitas Clinical and Research Center; Skin Pathology Lab; Rozzano-Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica, Dipartimento di Medicina dei Sistemi, Universita Tor Vergata; Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Humanitas Clinical and Research Center; Skin Pathology Lab; Rozzano-Milan Italy"},{"name":"Dermatology Unit, Department of Biomedical Sciences; Humanitas University; Rozzano-Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,7]]},"reference":[{"key":"10.1111\/dth.12565-BIB0001|dth12565-cit-0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/09546634.2014.880775","article-title":"Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice","volume":"26","author":"Armesto","year":"2015","journal-title":"Journal of Dermatological Treatment"},{"issue":"1 Suppl","key":"10.1111\/dth.12565-BIB0002|dth12565-cit-0003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/03946320140270S102","article-title":"Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: Focus on adalimumab","volume":"27","author":"Armuzzi","year":"2014","journal-title":"International Journal of Immunopathology Pharmacology"},{"issue":"1 Suppl","key":"10.1111\/dth.12565-BIB0003|dth12565-cit-0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/03946320140270S101","article-title":"The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases","volume":"27","author":"Blandizzi","year":"2014","journal-title":"International Journal of Immunopathology Pharmacology"},{"key":"10.1111\/dth.12565-BIB0004|dth12565-cit-0005","unstructured":"Blandizzi , C. 2013 http:\/\/www.sifweb.org\/docs\/sif_position_paper_anti_tnf_giu13.pdf"},{"key":"10.1111\/dth.12565-BIB0005|dth12565-cit-0006","first-page":"447","article-title":"Drug survival rates of biologic treatments in patients with psoriasis vulgaris","volume":"166","author":"Brunasso","year":"2012","journal-title":"British Association of Dermatologists"},{"key":"10.1111\/dth.12565-BIB0006|dth12565-cit-0007","unstructured":"Canadian Psoriasis Guidelines Committee 2009 Canadian guidelines for the management of plaque psoriasis http:\/\/www.dermatology.ca\/psoriasisguidelines"},{"key":"10.1111\/dth.12565-BIB0007|dth12565-cit-0008","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/CEOR.S66338","article-title":"Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study","volume":"6","author":"Degli Esposti","year":"2014","journal-title":"ClinicoEconomics and Outcomes Research"},{"key":"10.1111\/dth.12565-BIB0008|dth12565-cit-0009","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1365-2133.2007.07881.x","article-title":"Psoriasis has a major secondary impact on the lives of family members and partners","volume":"156","author":"Eghlileb","year":"2007","journal-title":"British Journal of Dermatology"},{"key":"10.1111\/dth.12565-BIB0009|dth12565-cit-0010","unstructured":"Enbrel\u00ae (Etanercept) 2015 Summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000262\/WC500027361.pdf"},{"key":"10.1111\/dth.12565-BIB0010|dth12565-cit-0011","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjd.12422","article-title":"Survival rate of antitumour necrosis factor-a treatments for psoriasis in routine dermatological practice: A multicentre observational study","volume":"169","author":"Esposito","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1111\/dth.12565-BIB0011|dth12565-cit-0012","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000345623","article-title":"Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: An observational long-term study","volume":"225","author":"Esposito","year":"2012","journal-title":"Dermatology"},{"key":"10.1111\/dth.12565-BIB0012|dth12565-cit-0013","unstructured":"European Medicines Agency 2016 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000481\/WC500202367.pdf"},{"key":"10.1111\/dth.12565-BIB0013|dth12565-cit-0014","doi-asserted-by":"crossref","first-page":"862969","DOI":"10.1155\/2014\/862969","article-title":"Drug retention rates and treatment discontinuation among anti-TNF-\u03b1 agents in psoriatic arthritis and ankylosing spondylitis in clinical practice","volume":"2014","author":"Fabbroni","year":"2014","journal-title":"Mediators Inflammation"},{"key":"10.1111\/dth.12565-BIB0014|dth12565-cit-0015","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the rule of tens","volume":"152","author":"Finlay","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"Suppl. 2","key":"10.1111\/dth.12565-BIB0015|dth12565-cit-0016","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/annrheumdis-2011-201036","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases","volume":"71","author":"Furst","year":"2012","journal-title":"Annals of Rheumatic Disorder"},{"key":"10.1111\/dth.12565-BIB0016|dth12565-cit-0017","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jcpt.12044","article-title":"Biological treatments for moderate-to-severe psoriasis: Indirect comparison","volume":"38","author":"Galvan-Banqueri","year":"2013","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"1","key":"10.1111\/dth.12565-BIB0017|dth12565-cit-0018","first-page":"8","article-title":"Retention rate of systemic drugs in patients with chronic placque psoriasi","volume":"1","author":"Gisondi","year":"2013","journal-title":"Clinical Dermatology"},{"key":"10.1111\/dth.12565-BIB0018|dth12565-cit-0019","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy. Results from the Nationwide Danish DANBIO Registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis & Rheumatism"},{"key":"10.1111\/dth.12565-BIB0019|dth12565-cit-0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.13343","article-title":"Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris","volume":"172","author":"Gniadecki","year":"2015","journal-title":"British Journal of Dermatology"},{"key":"10.1111\/dth.12565-BIB0020|dth12565-cit-0021","first-page":"1091","article-title":"Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris","volume":"164","author":"Gniadecki","year":"2011","journal-title":"British Association of Dermatologists"},{"key":"10.1111\/dth.12565-BIB0021|dth12565-cit-0022","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"Journal of American Academy of Dermatology"},{"issue":"5 Suppl 93","key":"10.1111\/dth.12565-BIB0022|dth12565-cit-0023","first-page":"S73","article-title":"Treatment of psoriatic arthritis: Management recommendations","volume":"33","author":"Gossec","year":"2015","journal-title":"Clinical Experimental Rheumatology"},{"key":"10.1111\/dth.12565-BIB0023|dth12565-cit-0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Annals of Rheumatic Disorder"},{"issue":"12","key":"10.1111\/dth.12565-BIB0024|dth12565-cit-0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2009.06.021","article-title":"Comorbidities in patients with psoriasis","volume":"122","author":"Gottlieb","year":"2009","journal-title":"The American Journal of Medicine"},{"key":"10.1111\/dth.12565-BIB0025|dth12565-cit-0026","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"Journal of American Academy of Dermatology"},{"key":"10.1111\/dth.12565-BIB0026|dth12565-cit-0027","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11926-012-0262-6","article-title":"How can psoriatic arthritis be diagnosed early?","volume":"14","author":"Haddad","year":"2012","journal-title":"Currents Rheumatology Reports"},{"key":"10.1111\/dth.12565-BIB0027|dth12565-cit-0028","unstructured":"Humira\u00ae (Adalimumab) 2015 Summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf"},{"key":"10.1111\/dth.12565-BIB0028|dth12565-cit-0029","unstructured":"Il Trattamento della Psoriasi Nell'adulto 2013"},{"key":"10.1111\/dth.12565-BIB0029|dth12565-cit-0030","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.13908","article-title":"Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register","author":"Iskandar","year":"2015","journal-title":"British Journal of Dermatology"},{"key":"10.1111\/dth.12565-BIB0030|dth12565-cit-0031","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1468-3083.2010.03654.x","article-title":"Psoriatic arthritis - What the dermatologist needs to know","volume":"24","author":"Laws","year":"2010","journal-title":"Journal of European Academy of Dermatology Venereology"},{"key":"10.1111\/dth.12565-BIB0031|dth12565-cit-0032","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.12543","article-title":"Adalimumab for the treatment of psoriasis in real life: A retrospective cohort of 119 patients at a single Spanish centre","volume":"169","author":"Lopez-Ferrer","year":"2013","journal-title":"British Journal of Dermatology"},{"key":"10.1111\/dth.12565-BIB0032|dth12565-cit-0033","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3899\/jrheum.150625","article-title":"Verna Wright lecture: Psoriatic arthritis: The need\u00a0for early intervention","volume":"93","author":"McHugh","year":"2015","journal-title":"Journal of Rheumatology Supplement"},{"key":"10.1111\/dth.12565-BIB0033|dth12565-cit-0034","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"Journal of American Academy of Dermatology"},{"key":"10.1111\/dth.12565-BIB0034|dth12565-cit-0035","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bjd.13001","article-title":"Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: A single-centre database analysis","volume":"171","author":"Menting","year":"2014","journal-title":"British Journal of Dermatology"},{"key":"10.1111\/dth.12565-BIB0035|dth12565-cit-0036","unstructured":"NICE Clinical Guideline Centre 2012 Psoriasis. The assessment and management of psoriasis"},{"key":"10.1111\/dth.12565-BIB0036|dth12565-cit-0037","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04225.x","article-title":"Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: Results of PRIDE, an open-label, multicentre, phase IIIb study","volume":"26","author":"Papp","year":"2012","journal-title":"Journal of European Academy of Dermatological Venereology"},{"issue":"Suppl 2","key":"10.1111\/dth.12565-BIB0037|dth12565-cit-0038","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.2310\/7750.2009.00022","article-title":"Adalimumab in the treatment of psoriasis: Pooled efficacy and safety results from three pivotal studies","volume":"13","author":"Papp","year":"2009","journal-title":"Journal of Cutaneous Medical Surgery"},{"key":"10.1111\/dth.12565-BIB0038|dth12565-cit-0039","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/jdv.12238","article-title":"Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points","volume":"28","author":"Puig","year":"2014","journal-title":"Journal of European Academy of Dermatology and Venereology"},{"key":"10.1111\/dth.12565-BIB0039|dth12565-cit-0040","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"Journal of American Academy of Dermatology"},{"key":"10.1111\/dth.12565-BIB0040|dth12565-cit-0041","first-page":"189","article-title":"Disease and treatment burden of psoriasis: Examining the impact of biologics","volume":"10","author":"Raval","year":"2011","journal-title":"Journal of Drugs Dermatology"},{"key":"10.1111\/dth.12565-BIB0041|dth12565-cit-0042","first-page":"179","article-title":"Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials","volume":"166","author":"Reich","year":"2012","journal-title":"British Association of Dermatologists"},{"key":"10.1111\/dth.12565-BIB0042|dth12565-cit-0043","unstructured":"Remicade\u00ae (Infliximab) 2015 Summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000240\/WC500050888.pdf"},{"issue":"Suppl. 66","key":"10.1111\/dth.12565-BIB0043|dth12565-cit-0044","first-page":"S28","article-title":"Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: Update from the Italian Society for Rheumatology","volume":"29","author":"Salvarani","year":"2011","journal-title":"Clinical Experimental Rheumatology"},{"key":"10.1111\/dth.12565-BIB0044|dth12565-cit-0045","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to severe psoriasis: Meta-analysis of randomized controlled trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"British Journal of Dermatology"},{"key":"10.1111\/dth.12565-BIB0045|dth12565-cit-0046","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN) 2010 Diagnosis and management of psoriasis and psoriatic arthritis in adults http:\/\/www.sign.ac.uk"},{"key":"10.1111\/dth.12565-BIB0046|dth12565-cit-0047","unstructured":"Simponi\u00ae (Golimumab) 2015 Summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000992\/WC500052368.pdf"},{"key":"10.1111\/dth.12565-BIB0047|dth12565-cit-0048","unstructured":"Stelara\u00ae, (ustekinumab) 2015 Summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000958\/WC500058513.pdf"},{"key":"10.1111\/dth.12565-BIB0048|dth12565-cit-0049","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheumatics"},{"issue":"5","key":"10.1111\/dth.12565-BIB0049|dth12565-cit-0050","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/bjd.13087","article-title":"Happy\u2019 drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: Results from the BioCAPTURE network","volume":"171","author":"den Reek","year":"2014","journal-title":"British Journal of Dermatology"},{"key":"10.1111\/dth.12565-BIB0050|dth12565-cit-0051","doi-asserted-by":"crossref","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration","volume":"147","author":"Vandenbroucke","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"10.1111\/dth.12565-BIB0051|dth12565-cit-0052","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"10.1111\/dth.12565-BIB0052|dth12565-cit-0053","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: A prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"Journal of Investigative Dermatology"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdth.12565","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/dth.12565\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:57:13Z","timestamp":1671818233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.12565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,7]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"URL":"https:\/\/doi.org\/10.1111\/dth.12565","archive":["Portico"],"relation":{},"ISSN":["1396-0296"],"issn-type":[{"type":"print","value":"1396-0296"}],"subject":[],"published":{"date-parts":[[2017,12,7]]}}}